Why the study?
Patients with AF and ACS are at high risk of ischemic events, but no single antithrombotic regimen fits all patients, requiring tailored therapy to balance bleeding and thrombotic risks.
In patients with AF and ACS/PCI, early use of a DOAC plus a P2Y12 inhibitor is generally optimal, while triple therapy should be reserved for those at high thrombotic risk.
Answers are grounded in this paper and cite their sources.
Supports dual therapy with full-dose DOAC plus P2Y12 early post-ACS/PCI in AF; leaves open optimal triple therapy duration in high-risk subgroups.
Patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) are at high risk of stroke, recurrent coronary ischemic events, and cardiovascular mortality. The composition of antithrombotic therapy including an oral anticoagulant and antiplatelet drug(s) should be tailored according to the individual patient's risk profile, to reduce the bleeding risk and maintain antithrombotic effect. There is no single antithrombotic treatment regimen that would fit to all patients with AF and ACS. However, available data promote the use of full‐dose direct oral anticoagulants (DOACs) (dabigatran 150 mg twice daily or apixaban 5 mg twice daily) or rivaroxaban 15 mg once daily in patients with AF and ACS or percutaneous coronary intervention (PCI). For many patients, a DOAC plus P2Y 12 inhibitor early after ACS and/or PCI would be optimal, whereas a longer course of triple therapy should be used in patients at high thrombotic risk.
No takes yet. Share an insight, caveat, or question.
Kozieł et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: